Zydus Cadila Recalls Over 10,000 Bottles of Allergy Drug In US
Indian drugmaker Zydus Cadila is recalling 10,200 bottles of an allergy-relief drug in the United States after another drug for high blood pressure was found in one of the bottles, the US Food and Drug Administration said on Friday.
The recall was voluntarily started by the company's U.S. unit, Zydus Pharmaceuticals USA Inc, on May 8, due to the presence of the high blood pressure medicine atenolol in a bottle containing the allergy drug, promethazine hydrochloride.
Promethazine hydrochloride is commonly used to treat allergic disorders, nausea, vomiting and difficulty sleeping, as well as for pre-operative sedation.
The FDA classified the recall as Class II, which means use of or exposure to the recalled products may cause temporary or medically reversible adverse health consequences.
The bottles being recalled carry an expiry date of September 2015, according to the FDA post.
"This was a voluntary recall by the company as a precautionary measure," a Zydus spokeswoman said in an email to Reuters.
Recalls of drugs are not uncommon.
However, Zydus's drug recall is the seventh this year by an Indian company, and follows those by other large drugmakers including Wockhardt Ltd, Ranbaxy Laboratories Ltd, Dr. Reddy's Laboratories Ltd, Lupin Ltd, Sun Pharmaceutical Industries Ltd and Glenmark Pharmaceuticals Ltd.
The incidents come at a time when the FDA has increased its scrutiny of Indian drugmakers after the agency banned exports from manufacturing plants of some top drugmakers, including Ranbaxy and Wockhardt, upon finding quality control lapses.
Copyright: Thomson Reuters 2014
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
-
Everything, Everywhere, All At Once: Dalal Street's Week To Forget | Joining The Dots
Visa curbs, a Starlink spat and cancer drug caps: what connects this week's shocks for Indian markets
-
India Is Going Abroad For Critical Minerals. But It May Take Years To Pay Off | The Reason Why
Although India's steps are in the right direction, they remain modest compared with India's growing dependence.